|
Video: What is a Stock Split?
|
|
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. According to our SRPT split history records, Sarepta Therapeutics has had 1 split. | |
|
Sarepta Therapeutics (SRPT) has 1 split in our SRPT split history database. The split for SRPT took place on July 12, 2012. This was a 1 for 6 reverse split, meaning for each 6 shares of SRPT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as Sarepta Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SRPT split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sarepta Therapeutics shares, starting with a $10,000 purchase of SRPT, presented on a split-history-adjusted basis factoring in the complete SRPT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/07/2014 |
|
End date: |
11/05/2024 |
|
Start price/share: |
$16.12 |
|
End price/share: |
$125.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
675.50% |
|
Average Annual Total Return: |
22.73% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$77,580.23 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
07/12/2012 | 1 for 6 |
|
|